Journal
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY
Volume 46, Issue 7, Pages 738-744Publisher
WILEY
DOI: 10.1111/pace.14711
Keywords
antiarrhythmic medication; atrial fibrillation; left ventricular hypertrophy
Ask authors/readers for more resources
This study retrospectively analyzed the medical records of 8204 atrial fibrillation patients who were prescribed antiarrhythmic medications. It found that among patients with left ventricular hypertrophy, amiodarone use was associated with a higher risk of mortality compared to other antiarrhythmic medications.
BackgroundAtrial fibrillation (AF) guidelines recommend amiodarone as the preferred antiarrhythmic medication (AAM) in patients with left ventricular hypertrophy (LVH), due to potential pro-arrhythmic risk with other AAM. However, there are limited data to support this assertion. MethodsWe retrospectively analyzed the records of 8204 patients who were prescribed AAM for AF and had transthoracic echocardiogram (TTE) at the multicenter, VA Midwest Health Care Network from 2000 to 2021. We excluded patients without LVH (septal or posterior wall dimension <= 1.4 cm). The primary outcome variable was all-cause mortality during antiarrhythmic therapy or within 6 months after stopping it. Propensity-stratified analyses were performed between amiodarone versus non-amiodarone (Vaughan-Williams Class I and III) AAM. ResultsA total of 1277 patients with LVH (mean age 70.2 +/- 9.5 years) were included in the analysis. Of these, 774 (60.6%) were prescribed amiodarone. Baseline characteristics of the two comparison groups were similar after propensity adjustment. After a median 1.40 years of follow-up, 203 (15.9%) patients died. Incidence rates per 100 patient-year follow-up was 9.02 (7.58-10.66) for amiodarone and 4.98 (3.91-62.56) for non-amiodarone. In propensity-stratified analysis, amiodarone use was associated with 1.58 times higher risk of mortality (95% CI 1.03-2.44; p = .038). Sub-group analysis in 336 (26.3%) patients with severe LVH showed no difference in mortality (HR 1.41, 95% CI 0.82-2.43, p = .21). ConclusionAmong patients with AF and LVH, amiodarone was associated with a significantly higher mortality risk than other AAM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available